title: [Treatment of malignancy associated hypercalcemia].
abstract: Malignancy associated hypercalcemia (MAH) is a paraneoplastic syndrome that impairs the quality of life and that can be a direct cause of death. MAH is classified into two major categories : humoral hypercalcemia of malignancy (HHM) and local osteolytic hypercalcemia (LOH) . Bisphosphonates are the gold standard of treatment for MAH, because enhanced resorption causing a massive calcium mobilization from bone plays a central role in the pathogenesis of MAH. Calcitonin can be used initially as an adjunctive therapy, because it takes a few days for bisphosphonates to be effective. Saline infusion is also necessary to improve dehydration and renal insufficiency inevitably accompanying MAH.
authors: Third Department of Medicine, Teikyo University Chiba Medical Center, Japan.
authors: Nobuyuki
authors: N
authors: Tai
authors: Daisuke
authors: D
authors: Inoue
mesh_terms: D001862:Bone Resorption / Q000188:drug therapy; D002116:Calcitonin / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000150:complications*; D010257:Paraneoplastic Syndromes / Q000188:drug therapy* / Q000209:etiology; D044162:Parathyroid Hormone-Related Protein / Q000378:metabolism
chemical_list: D004164:Diphosphonates; D044162:Parathyroid Hormone-Related Protein; D002116:Calcitonin